Investigational Drug Details
| Drug ID: | D068 |
| Drug Name: | Cenicriviroc |
| Synonyms: | Cenicriviroc |
| Type: | Chemical drug |
| DrugBank ID: | DB11758 |
| DrugBank Description: | Cenicriviroc has been used in trials studying the treatment of HIV-infection/AIDS, AIDS Dementia Complex, Nonalcoholic Steatohepatitis, Human Immunodeficiency Virus, and HIV-1-Associated Cognitive Motor Complex. |
| PubChem ID: | 11285792 |
| CasNo: | 497223-25-3 |
| Repositioning for NAFLD: | No |
| SMILES: | C(C(C)C)N1c2c(cc(cc2)c2ccc(cc2)OCCOCCCC)C=C(CCC1)C(=O)Nc1ccc(cc1)S(=O)Cc1n(CCC)cnc1 |
| Structure: |
|
| InChiKey: | PNDKCRDVVKJPKG-UHFFFAOYSA-N |
| Molecular Weight: | 696.958 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | CCR2 inhibitor; CCR5 inhibitor |
| Therapeutic Category: | Anti-fibrosis |
| Clinical Trial Progress: | Phase 3 terminated (NCT03028740: This study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0132 | NCT02330549 | Phase 2 | Completed | Has Results | July 17, 2015 | October 11, 2019 | Details |
| L0150 | NCT03059446 | Phase 2 | Terminated | Has Results | February 14, 2017 | February 2, 2022 | Details |
| L0229 | NCT03517540 | Phase 2 | Completed | Has Results | September 11, 2018 | January 24, 2022 | Details |
| L0318 | NCT02217475 | Phase 2 | Completed | Has Results | September 18, 2014 | May 10, 2019 | Details |
| L0319 | NCT03028740 | Phase 3 | Terminated | Has Results | April 5, 2017 | March 10, 2022 | Details |
| L0557 | EUCTR2016-004566-26-DE | Phase 3 | Authorised | No Results Available | 22/02/2017 | 9 October 2017 | Details |
| L0773 | CTRI/2019/01/017014 | Phase 2 | Recruiting | No Results Available | 09/01/2019 | 24 November 2021 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00838 | 34951993 | Gastroenterology | Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | Details |
| A03482 | 33987427 | Ann Transl Med | Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. | Details |
| A03484 | 33987424 | Ann Transl Med | Non-alcoholic fatty liver diseases: current challenges and future directions. | Details |
| A03845 | 33849361 | Expert Opin Drug Discov | The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. | Details |
| A04097 | 33761646 | Medicine (Baltimore) | The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. | Details |
| A04749 | 33515800 | Ann Hepatol | Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. | Details |
| A05080 | 33385317 | J Dig Dis | Efficacy and safety of drugs for nonalcoholic steatohepatitis. | Details |
| A05119 | 33368954 | Diabetes Obes Metab | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. | Details |
| A05376 | 33278029 | Pharmacotherapy | Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | Details |
| A06057 | 33025657 | Liver Int | Recent advances targeting C-C chemokine receptor type 2 for liver diseases in monocyte/macrophage. | Details |
| A07203 | 32583961 | Clin Transl Sci | Evolving Role for Pharmacotherapy in NAFLD/NASH. | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | Details |
| A08581 | 32052857 | Hepatology | New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. | Details |
| A08905 | 31943293 | Hepatology | Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | Details |
| A09084 | 31881392 | Contemp Clin Trials | Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. | Details |
| A09473 | 31731005 | Contemp Clin Trials | A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. | Details |
| A10083 | 31495973 | Hepatol Res | Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. | Details |